Dear Editor,

Sepsis and septic shock are life-threatening organ dysfunctions caused by a dysregulated host response to severe infection [1]. Inflammatory cytokines play a pivotal role in the progression of sepsis and cause dysregulation of vital organ functions, possibly leading to organ failure and death. To clear key cytokines in septic patients the cytokine adsorber CytoSorb® is increasingly used, despite absence of hard evidence for a beneficial effect on patient-centered outcomes [2]. Moreover, concerns have been raised that CytoSorb® unintentionally adsorbs drugs such as meropenem [3]. Previous in vitro experiments suggested that the CytoSorb® filter has an adsorptive capacity, for meropenem, of about 400 mg [3]. In a case report, removal of meropenem was suspected in a critically ill patient [5], yet recent in vivo data in healthy pigs suggested a negligible increase in clearance (6.3%) [4]. To date, reliable quantitative clinical data are missing [2].

We analyzed therapeutic drug monitoring data in critically ill patients undergoing continuous veno-venous hemodialysis with and without CytoSorb® treatment (44 CytoSorb® treatments, 25 patients, 333 serum samples including 114 during CytoSorb® treatment). Meropenem pharmacokinetics was characterized using nonlinear mixed-effect modeling (NONMEM 7.4). A classical two-compartment model best described the observed concentrations. To assess whether clearance differed without versus during CytoSorb® treatment, three approaches were applied: (i) quantification of a possible proportional increase in clearance during CytoSorb® treatment, (ii) investigation of (non)saturable adsorption at the CytoSorb filter using different adsorption submodels (constant adsorption, linear and hyperbolic decrease of adsorption); and (iii) model parameter re-estimation, excluding samples collected during CytoSorb® treatment and evaluating how well these parameters predicted the concentrations during CytoSorb® treatment (Supplementary File). However, none of these approaches revealed a significant ($p < 0.05$) or relevant effect of CytoSorb® therapy on meropenem concentrations. Both the proportional increase of approach (i) and the maximum adsorption estimated in approach (ii) were negligibly small (< 3.7% total clearance) and could not be estimated precisely (relative standard error $\geq 110\%$). The re-estimated model even revealed a small underprediction (0.42 mg/L, 2.6%) of concentrations during CytoSorb® treatment, whereas an overprediction would indicate adsorption. Figure 1 shows the predicted concentration–time profile of a representative patient, based on the pharmacokinetic model excluding CytoSorb® samples and the observed concentrations both during and without CytoSorb® treatment. Although not included in the model development, the samples taken during CytoSorb® treatment were well predicted by the model, showing that there was no clinically relevant reduction of meropenem concentrations. A similar figure supporting the same conclusion for all patients, as well as patient characteristics and details of
the modeling approach, can be found in the supplementary file.

Overall, no clinically relevant adsorption of meropenem by the cytokine adsorber CytoSorb® was observed in the investigated critically ill patient population. Consequently, neither additional dosing nor more frequent monitoring of meropenem is necessary during the application of CytoSorb®. Our findings most likely do not translate to other drugs and antibiotics, and we therefore emphasize that every drug needs to be investigated separately.

Acknowledgements
CytoMero collaboration team: Robin Mieche-t—Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kielchstr. 31, 12169 Berlin, Germany. Ines Schroeder—Department of Anaesthesiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany, Michael Paal—Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany, Marchioninistr. 15, 81377 Munich, Germany, Michael Vogeser—Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany, Marchioninistr. 15, 81377 Munich, Germany, Michael Irlbeck—Department of Anaesthesiology, University Hospital, LMU Munich, Germany, Marchioninistr. 15, 81377 Munich, Germany, Josef Briegel—Department of Anaesthesiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany, Johannes Zander—Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany, Marchioninistr. 15, 81377 Munich, Germany. Laboratory Dr. Brunner, Luisenstr. 7e, 78464 Konstanz, Germany, Wilhelm Huisinga—Institute of Mathematics, Universität Potsdam, Karl-Liebknecht-Str. 24-25, 14476 Potsdam, Germany.

Funding
Open Access funding enabled and organized by Projekt DEAL. This work was funded by institutional sources. UL acknowledges the funding of research by the Munich Clinician-Scientist Program, a funding program of the Medical Faculty of the LMU Munich for young scientists. CS acknowledges financial support from the local university’s program for young scientists.

Declarations

Conflicts of interest
CX and WH report grants from an industry consortium (AbbVie Deutschland GmbH & Co. KG, AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal GmbH, F. Hoffmann-La Roche Ltd, Merck KGaA and SANOFI) for the PharmMetX PhD program. CX reports grants from the Innovative Medicines Initiative-Joint Undertaking ("DDMoRe"), Dmia Ltd, the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (JPIAMR) and the European Commission within the Horizon 2020 framework program ("FAIR"), all outside the submitted work.

Ethics approval
This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval and consent were obtained from the Institutional Review Board of the Medical Faculty of the Ludwig-Maximilians-Universität München (Munich, Germany) [registration No. 428-12 and 18-578].

Open Access
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Accepted: 16 July 2021
Published online: 14 September 2021

References
1. Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810. https://doi.org/10.1001/jama.2016.0287
2. Poli EC, Rimmelé T, Schneider AG (2019) Hemoadsorption with CytoSorb®. Intensive Care Med 45:236–239. https://doi.org/10.1007/s00134-018-5464-6
3. König C, Röhr AC, Frey OR et al (2019) In vitro removal of anti-infective agents by a novel cytokine adsorbent system. Int J Artif Organs 42:57–64. https://doi.org/10.1177/039139881812601
4. Schneider AG, André P, Scheier J et al (2021) Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption. Sci Rep 11:10493. https://doi.org/10.1038/s41598-021-89965-z
5. Zoller M, Döbbeler G, Maier B et al (2015) Can cytokine adsorber treatment affect antibiotic concentrations? A case report. J Antimicrob Chemother 70:2169–2171. https://doi.org/10.1093/jac/dkv068